Adma Biologics, Inc. ADMA
No buyback or stock pay figures in its 10-K data yet
XBRL, 10-KWhere the cash came from and where it went
FY2025, from the cash flow statement in the 10-K, added up
The same cash, step by step
Came from
| Operating cash flow | $50.4M |
| Shares sold | $3.0M |
| Cash on hand used | $15.5M |
Went to
| Capital spending | $22.6M |
| Buybacks | $31.9M |
| Other, net investments bought and sold, other financing and investing lines, and exchange rates |
$14.4M |
Each number is a line of the cash flow statement as the company tagged it. "Other, net" is what those lines do not cover (investments bought and sold, other financing and investing lines, and exchange rates); Tickdelta does not estimate it.
Where the operating cash went, year by year
FY2016 to FY2025 · cash flow statements, 10-K XBRL
| Fiscal year | Operating cash | Capital spending | Buybacks | Debt repaid |
|---|---|---|---|---|
| Dec 31, 2025 | $50.4M | $22.6M | $31.9M | - |
| Dec 31, 2024 | $118.7M | $8.2M | - | - |
| Dec 31, 2023 | $8.8M | $4.8M | - | - |
| Dec 31, 2022 | -$59.5M | $13.9M | - | - |
| Dec 31, 2021 | -$112.4M | $13.5M | - | - |
| Dec 31, 2020 | -$102.0M | $12.7M | - | $13.9M |
| Dec 31, 2019 | -$76.2M | $3.8M | - | $30.0M |
| Dec 31, 2018 | -$62.7M | $2.1M | - | - |
| Dec 31, 2017 | -$37.3M | $2.7M | - | - |
| Dec 31, 2016 | -$18.3M | $73K | - | - |
| Added up | -$290.4M | $84.4M | $31.9M | $44.0M |
Each bar is one fiscal year; its colours add up to what the cash flow statement says the company spent on each line, and the line across it is that year's operating cash flow. Spending above the line was paid from new debt, shares sold or cash on hand. A bar part links to the 10-K it comes from. A line the company did not report is left out, not estimated, so the shares are of operating cash only and can add up to more or less than 100%. Debt repaid is the gross amount, so refinanced debt is counted each time it is repaid. A reading aid, not a grade: Tickdelta does not say whether a split was good. Banks and insurers are left out.
Buybacks, dividends and share count
Year by year · XBRL, each 10-K
No buyback or share count data in the 10-K XBRL.
Buybacks month by month, and what is left to buy
Share buybacks · 10-Q, Part II Item 2, latest 4 quarters
“Repurchases of Equity Securities In May 2025, the Board authorized a share repurchase program of up to $500.0 million of our outstanding shares of common stock (the “Repurchase Program”).”
10-Q, Part II Item 2
Spent each month (shares × average price)
| Month | Shares bought | Average price |
|---|---|---|
| Aug 2026 | 1,303,650 | $9.61 |
| Jul 2026 | 1,418,913 | $8.83 |
| Jun 2026 | 482,235 | $7.88 |
| May 2026 | 5,770,688 | $5.60 |
| Apr 2026 | 808,615 | $10.83 |
| Mar 2026 | 6,519,788 | $16.37 |
| Feb 2026 | 234,368 | $15.75 |
| Sep 2025 | 507,824 | $15.67 |
Shares and average price are the numbers in the 10-Q table, row by row; "shares × price" is our multiplication of the two. A row with a price of "-" is an accelerated repurchase paid up front, where the 10-Q does not give a price yet. A 10-Q that counts shares in millions gives a rounded number, shown as "about". Shares withheld for employees' taxes are not in this table. A month that no 10-Q table gives, or that this page could not read with confidence, is not shown.
What it paid for each share it bought back
Price paid · 10-K, statement of shareholders' equity
What ADMA paid on average for each share it bought back, each fiscal year: dollars spent divided by shares bought, both from the 10-K.
| Fiscal year to | Shares bought | Spent | Average price |
|---|---|---|---|
| Dec 31, 2025 | 1.92M | $32.1M | $16.72 |
| Dec 31, 2014 | 58K | $477K | $8.22 |
Shares and dollars from the statement of shareholders' equity (the cash flow line also counts shares withheld for taxes, so it is not used). Share counts filed before a stock split are put on today's count. A year where the 10-K does not tag both numbers is left out.
What the 10-Ks show for each CEO's years
Each CEO's years · the CEO of each fiscal year as named in the proxy's pay versus performance table
Mr. Adam Grossman
- Operating cash flow
- $6.0M
- Capital spending
- $63.0M
- Buybacks
- $31.9M
- Stock-based pay
- $48.5M
- Diluted shares since FY2020
- +184.3%
- Revenue since FY2020
- +1108%
- Debt since FY2020
- -$20.8M
- CEO pay (reported)
- $31.2M
Sources
The cash flow statement, dividends per share and diluted share count in each 10-K's XBRL; Part II Item 2 of each 10-Q for monthly buybacks; offering prospectuses (S-3, 424B) for new shares; Form D data sets for private raises.
Also
CEO pay: what the CEO was paid over the same years.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ADMA/export.csv") into a cell.